Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Payables (2016 - 2025)

Avanos Medical's Payables history spans 11 years, with the latest figure at $54.2 million for Q3 2024.

  • For Q3 2024, Payables rose 4.03% year-over-year to $54.2 million; the TTM value through Sep 2024 reached $54.2 million, up 4.03%, while the annual FY2023 figure was $56.3 million, 17.08% down from the prior year.
  • Payables for Q3 2024 was $54.2 million at Avanos Medical, up from $51.4 million in the prior quarter.
  • Across five years, Payables topped out at $75.9 million in Q3 2020 and bottomed at $51.4 million in Q2 2024.
  • The 5-year median for Payables is $62.7 million (2022), against an average of $62.3 million.
  • The largest annual shift saw Payables crashed 50.6% in 2020 before it increased 20.39% in 2022.
  • A 5-year view of Payables shows it stood at $67.6 million in 2020, then fell by 16.57% to $56.4 million in 2021, then rose by 20.39% to $67.9 million in 2022, then fell by 17.08% to $56.3 million in 2023, then dropped by 3.73% to $54.2 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Payables are $54.2 million (Q3 2024), $51.4 million (Q2 2024), and $57.0 million (Q1 2024).